METAP1 and breast carcinoma: In comparison to DMSO-only treated cells, knockdown of Metap1 or Metap2 stalled murine PyB6-TA cells in G1-phase and human MDAMB-TA cells in G2-phase, thus leading to an impaired cell cycle progression to S-phase in murine and human breast cancer cells (Figure 5E).